EP1150726A1 - Highly-mineralized osteogenic sponge compositions, and uses thereof - Google Patents

Highly-mineralized osteogenic sponge compositions, and uses thereof

Info

Publication number
EP1150726A1
EP1150726A1 EP00905989A EP00905989A EP1150726A1 EP 1150726 A1 EP1150726 A1 EP 1150726A1 EP 00905989 A EP00905989 A EP 00905989A EP 00905989 A EP00905989 A EP 00905989A EP 1150726 A1 EP1150726 A1 EP 1150726A1
Authority
EP
European Patent Office
Prior art keywords
osteogenic
sponge
bone
matrix material
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00905989A
Other languages
German (de)
French (fr)
Other versions
EP1150726B1 (en
Inventor
William F. Mckay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDGI Holdings Inc
Original Assignee
SDGI Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SDGI Holdings Inc filed Critical SDGI Holdings Inc
Publication of EP1150726A1 publication Critical patent/EP1150726A1/en
Application granted granted Critical
Publication of EP1150726B1 publication Critical patent/EP1150726B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

  • the present invention relates generally to osteogenic compositions. Specifically, the present invention relates to an osteogenic sponge composition effective for the induction of new bone growth in animals.
  • Bone grafting has been commonly used to augment healing in the treatment of a broad range of musculoskeletal disorders. This procedure has several disadvantages. If the bone material is obtained from donors of the same species, such as an allograft, an increased risk of disease transmission and immune reaction exists. Bone material surgically removed from the patient, known as an autograft, is also undesirable because a sufficient amount of autogenous bone may not be available and the additional surgery necessary to obtain the autograft increases the risk of infection. Due to the need for safer bone graft materials, efforts have been directed to finding bone graft substitutes.
  • Candidate compositions include collagen and a bioceramic, such as hydroxyapatite, as these components are the chief structural materials in bone tissue.
  • Bioceramics provide a porous matrix which encourages some new bone growth but, when used in powdered form, give rise to foreign body-giant cell reactions.
  • Other compositions include demineralized bone powder and collagen. The osteogenic potential of these compositions have been found to be less than satisfactory.
  • the invention provides in one preferred embodiment an osteogenic sponge composition useful for the induction of new bone growth in a mammal.
  • This composition includes a resorbable sponge matrix material and an osteogenic factor, preferably one that preferably stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in the sponge matrix material.
  • the resorbable sponge matrix material is desirably a three- dimensionally stable yet flexible material, facilitating its use as an implant.
  • the osteogenic factor is usually incorporated in an amount that causes an increased rate of resorption of said sponge matrix material in a mammal.
  • the composition also includes a particulate mineral having an average particle diameter of at least about 0.5 mm embedded in the resorbable sponge matrix material, wherein the particulate mineral present in a weight ratio of at least 4: 1 relative to the resorbable sponge matrix material so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor. More preferred compositions are even more highly mineralized, for example wherein the particulate mineral is present in a weight ratio of at least about 10: 1 relative to the resorbable sponge matrix material.
  • the particulate mineral is desirably formed of a synthetic calcium phosphate ceramic or of bone, especially cortical bone.
  • the osteogenic factor is most preferably BMP-2 or LMP, or comprises a nucleotide sequence encoding BMP-2 or LMP.
  • Another embodiment of the present invention provides a method for inducing bone growth in a primate.
  • the method includes a first step of providing an osteogenic sponge composition having a resorbable sponge matrix material and an osteogenic factor that stimulates osteoblasts and osteoclasts incorporated in the sponge matrix material in an amount that causes an increased rate of resorption of the sponge matrix material in the primate.
  • Particulate mineral having an average particle diameter of at least about 0.5 mm is embedded in said resorbable sponge matrix material and present in a weight ratio of at least 4: 1 relative to the resorbable sponge matrix material, so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor.
  • This osteogenic sponge composition is implanted in the primate in a void in which bone growth is desired, with the osteogenic sponge composition providing a scaffold for a duration sufficient for osteoid ingrowth through the void.
  • Particularly preferred methods involve bone ingrowth to attain spinal fusions in humans.
  • an osteogenic sponge composition effective for the induction of new bone growth in a mammal (especially a primate) that includes a carrier consisting essentially of a resorbable sponge matrix with particulate mineral embedded in the resorbable sponge matrix, wherein the particulate mineral is present in an amount constituting at least about 95% by weight of the carrier.
  • An osteogenic factor that stimulates osteoblasts and osteoclasts is incorporated in said carrier.
  • a still further aspect of the invention provides a highly mineralized sponge implant device consisting essentially of a resorbable sponge matrix formed of collagen and having particulate biocompatible mineral embedded within said matrix.
  • the device is comprised 1% to 3% by weight of the collagen and 97% to 99% by weight of the particulate biocompatible mineral.
  • an osteogenic factor can be incorporated in such an implant.
  • a further embodiment of the invention provides an interbody spinal fusion device that includes a load bearing member sized for insertion between adjacent vertebrae and any one of the aforementioned compositions retained by the load bearing member.
  • Such fusion devices can be used in inventive interbody spinal fusion methods mammals, wherein the devices are appropriately implanted to facilitate spinal fusion.
  • a particular feature of the present invention relates to the discovery that the inclusion of an osteogenic factor, especially an osteoblast- and osteoclast-stimulating osteogenic factor, in a resorbable sponge composition causes a substantially accelerated resorption of the sponge. This rapid resorption can diminish or eliminate the capacity of the sponge composition to effectively stimulate and support new bone formation in a void filled with the sponge composition. This is particularly the case in primates, including humans, in which the rate of new bone formation is relatively slow.
  • Objects of the present invention are to provide osteogenic sponge compositions effective for the induction of bone growth in mammals, particularly primates, including humans, and related methods and devices.
  • FIGs. 1 and 2 depict a digitized images of computerized tomography (CT) scans of an L4-L5 posterolateral spinal fusions performed on rhesus monkeys as described in Example 5 (top panels, section through superior transverse processes; middle panels, section through disc space; lower panels, section through inferior transverse processes).
  • CT computerized tomography
  • the invention relates in certain aspects to osteogenic sponge compositions effective for the induction of new bone growth in mammals and methods for inducing bone growth in mammals.
  • the present invention features osteogenic sponge compositions effective for use in primates, wherein the compositions exhibit high osteoinductive potential and provide a lasting mineral scaffold to support bone ingrowth.
  • Such preferred compositions include a porous, resorbable sponge carrier, such as collagen in sponge form, and an osteogenic factor that stimulates the action of both osteoblasts (which biologically facilitate the formation of bone) and osteoclasts (which biologically facilitate the resorption of bone).
  • an effective inductive amount of an osteogenic factor such as a bone morphogenetic protein (BMP)
  • BMP bone morphogenetic protein
  • non-mineralized sponge compositions may be highly effective for repair of bone defects in lower animals, such as mice, that have a faster bone growth rate, they are less effective in large animals such as primates, including humans.
  • a feature of the present invention is the provision of an osteogenic composition in the form of a sponge that includes a substantial amount of a relatively slowly-resorbed mineral component that remains at the implant site after the carrier has been rapidly resorbed, in order to provide a scaffold for new bone formation that is not prematurely resorbed due to the osteoclastic potentiation by the bone morphogenic protein in the composition.
  • the present invention also provides methods for using such osteogenic compositions in treatment of bone trauma, disease and defects, for artificial arthrodeses and for other treatment where new bone formation is desired, especially in primates, including humans.
  • the sponge matrix material is preferably collagenous.
  • Naturally occurring collagens may be subclassified into several different types depending on their amino acid sequence, carbohydrate content and presence or absence of disulfide crosslinks.
  • Types I and III collagen are two of the most common subtypes of collagen. Type I collagen is present in skin, tendon and bone whereas Type III collagen is found primarily in skin.
  • the collagen in the composition may be obtained from skin, bone, tendon, or cartilage and purified by methods known in the art. Alternatively, the collagen may be purchased commercially.
  • the collagen in the composition is preferably Type I bovine collagen.
  • the collagen carrier can further be atelopeptide collagen and/ or telopeptide collagen.
  • both non-fibrillar and fibrillar collagen may be used.
  • Non-fibrillar collagen is collagen that has been solubilized and has not been reconstituted into its native fibrillar form.
  • the sponge carrier may also be formed of other natural or synthetic polymeric materials, in addition to or as an alternative to collagen.
  • the sponge carrier may be formed of gelatin (e.g. foamed gelatin), in addition collagen or as an alternative to collagen.
  • gelatin e.g. foamed gelatin
  • Other natural and synthetic polymers are also known for the formation of biocompatible sponge materials, and can be used herein.
  • compositions of the invention also include an osteoinductive factor, such as an osteoinductive protein or a nucleotide sequence encoding an osteoinductive protein operably associated with a promoter (e.g. provided in a vector such as a viral vector) which drives expression of the gene in the animal recipient to produce an effective amount of the protein.
  • the osteogenic factor utilized in the present invention can be one that stimulates production or activity of osteoblasts and osteoclasts.
  • the factor is preferably a bone morphogenetic protein (BMP) or a LIM mineralization protein (LMP), or comprises a nucleotide sequence encoding a BMP or LMP.
  • Recombinant human BMPs are preferred, and may be commercially obtained or prepared as described and known in the art, e.g. in U.S. Patent Nos. 5, 187,076 to Wozney et al.; 5,366,875 to Wozney et al.; 4,877,864 to Wang et al.; 5, 108,932 to Wang et al.; 5, 1 16,738 to Wang et al.; 5,013,649 to Wang et al.; 5, 106,748 to Wozney et al; and PCT Patent Nos.
  • the osteoinductive factor may be isolated from bone.
  • Methods for isolating BMP from bone are described in U.S. Patent no. 4,294,753 to Urist and Urist et al., PNAS 371, 1984.
  • Recombinant human BMP-2 rhBMP-2
  • rhBMP-4 recombinant human BMP-4
  • rhBMP-7 recombinant human BMP- 7 or heterodimers thereof are most preferred.
  • the osteoinductive factor may also be LIM mineralization protein (LMP) or a suitable vector incorporating a gene encoding the same operably associated with a promotor, as described in WO99/06563 (see also genbank accession No. AF095585).
  • LMP LIM mineralization protein
  • a suitable vector incorporating a gene encoding the same operably associated with a promotor as described in WO99/06563 (see also genbank accession No. AF095585).
  • LMP LIM mineralization protein
  • a suitable vector incorporating a gene encoding the same operably associated with a promotor as described in WO99/06563 (see also genbank accession No. AF095585).
  • the particulate mineral component includes a natural or synthetic mineral that is effective in providing a scaffold for bone ingrowth as the resorbable carrier is resorbed.
  • the mineral may be, for example, bone, especially cortical bone, or a synthetic bioceramic such as a biocompatible calcium phosphate ceramic.
  • Illustrative ceramics include tricalcium phosphate, hydroxyapatite, and biphasic calcium phosphate. These mineral components may be purchased commercially or obtained or synthesized by methods known in the art.
  • Biphasic calcium phosphate is a particularly preferred synthetic ceramic for use in the invention.
  • such biphasic calcium phosphate with have a tricalcium phosphate:hydroxyapatite weight ratio of about 50:50 to about 95:5, more preferably about 70:30 to about 95:5, even more preferably about 80:20 to about 90: 10, and most preferably about 85: 15.
  • the amount of mineral in the osteogenic sponge composition must be sufficient to provide a scaffold that will remain in the patient for a period of time sufficient for the formation of osteoid in the void for which bone growth is desired. Typically, this period of time will be about 6 to about 8 weeks.
  • the minimum level of mineral that must be present in the composition is also dependent on the activity of the BMP in the composition; the higher the activity of the BMP, the greater the content of the mineral matrix required to counter the osteoclastic potentiation of the BMP.
  • the rate of resorption of the resorbable carrier also increases as the BMP concentration increases.
  • the particulate minera resorbable sponge matrix weight ratio will be at least about 4: 1, more preferably at least about 10: 1.
  • the particulate mineral will constitute at least 95% by weight of the sponge implant.
  • highly effective sponge carrier devices are provided wherein they comprise about 97% to about 99% by weight particulate mineral and about 1% to about 3% of the collagen or other sponge-forming matrix material.
  • the mineral component have an average particle size of at least about 0.5 mm, more preferably about 0.5 mm to about 5 mm, and most preferably about 1 mm to about 3 mm.
  • a collagen slurry may be formed as known and preferably is chilled to increase its viscosity to help suspend the porous particulate mineral component.
  • the porous particulate mineral is dispersed into the collagen slurry and gently mixed. After the porous particulate mineral component is uniformly dispersed in the slurry, the slurry is poured into sterile trays or other forms and freeze dried. The sheets of composite sponge are then removed from the freeze drier and exposed to a gluteraldehyde cross-linking agent.
  • the composite sponge formed is generally three -dimensionally stable and can be sterilized and packaged in accordance with known procedures.
  • the dimensions of the sponge produced may vary depending on the application. Dimensions of a typical sponge are, for example, about 10 cm (length) x 7.5 cm (width) x 0.35 cm (height).
  • BMP or other osteogenic factors may be included in the formed sponge by combining the BMP with a liquid carrier as known in the art and infusing the liquid into the sponge.
  • osteogenic enhancing factors include host compatible osteogenic progenitor cells, autographic bone marrow, allographic bone marrow, transforming growth factor- ⁇ , fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, microglobulin- ⁇ , antibiotics and steroids.
  • methods for inducing bone growth in mammals include providing the above-described osteogenic sponge composition and implanting the composition at a site at which bone growth is desired, e.g., to treat a disease, defect or location of trauma, and/or to promote artificial arthrodesis.
  • the hydrated sponge composition may be rolled up prior to packing the sponge into the implantation site.
  • the osteogenic sponge composition will effectively induce and support ingrowth of bone into the desired area even in a primate such as a human that exhibits a relatively slow rate of bone formation compared to smaller mammals, such as rodents or rabbits.
  • a primate such as a human that exhibits a relatively slow rate of bone formation compared to smaller mammals, such as rodents or rabbits.
  • the collagen carrier is resorbed relatively quickly, the substantial mineral component remains as a scaffolding to support new bone growth in and through the desired area.
  • the above osteogenic sponge compositions of the present invention are especially advantageous when used in bones or bone portions that exhibit only low to moderate vascularization.
  • Such low to moderate vascularized regions exhibit low rates of bone formation so rapid resorption of a carrier poses a problem.
  • Examples of low to moderate vascularized sites include, for example, transverse processes or other posterior elements of the spine.
  • An especially preferred use of the sponge compositions of the present invention is as an implant to promote arthrodesis between vertebrae in spinal fusions in humans or other primates, including interbody, posterior and/or posterolateral fusion techniques.
  • the rate of bone formation in the primate spine is relatively slow overall and thus will benefit generally from the present invention, the elements to be fused in posterior and posterolateral fusions exhibit particularly low levels of vascularization and thus fusions of these elements are expected to benefit markedly from the invention.
  • the osteogenic sponge compositions can be incorporated with a load-bearing member used in a spinal fusion, including hollow spinal cages, dowels or other devices known in the art having a pocket, chamber or other mechanism for retaining the osteogenic sponge composition.
  • the load-bearing member desirably will have a compressive strength of at least about 10,000 N. Suitable such load bearing members are described, for example in U.S. Patent Nos. 5522899, 5785710, 5776199 and 5814084, each of which is hereby incorporated by reference in its entirety.
  • This composite slurry was poured into a 7.5 cm x 10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETC) gas sterilization.
  • the present study was performed to determine the effect of the osteogenic sponge compositions of the present invention on spinal fusion.
  • the experimental group included two adult rhesus monkeys [Macaca mulatto).
  • the monkeys were anesthetized with 3-5 mg/kg telazol intramuscularly (i.m.).
  • the anesthesia was maintained with 1.5-2.0% isoflurane.
  • animals were shaved, prepared with betadine and sterily draped.
  • the surgical site was infiltrated with 10-15 ml of 0.25% marcaine to aid with immediate postoperative analgesia.
  • a midlineposterior skin incision was made over the lumbar spine.
  • the paraspinal muscles were reflected using elevators, exposing the lamina and the transverse processes of the L4 and L5 vertebral bodies.
  • the transverse processes of the two vertebrae to be fused were decorticated with an electric burr.
  • Composite sponges having dimension of 3.5 cm x 1.4 cm x 0.35 cm, were prepared using techniques as described in Examples 1 and 2.
  • the sponges included, on a weight basis, 97% biphasic calcium phosphate (15% hydroxyapatite and 85% tricalcium phosphate, 1 mm particle size) and 3% collagen.
  • Recombinant human BMP-2 (rhBMP-2) was prepared at a concentration of 3.0 mg/ml in a buffered solution. Each sponge was infused with 1.5 ml of the rhBMP-2 solution.
  • the sponges were placed in the paraspinal bed directly on top of and bridging the two adjacent transverse processes.
  • the sponges were placed bilaterally, with two sponges (one on top of the other) on each side of the spine, resulting in a total dose of 9 mg rhBMP-2 per implant site.
  • the animals were allowed to recover and move around ad libitum without restrictions during the study period.
  • the spines were manually assessed for fusion upon sacrifice
  • FIGS. 1 and 2 show the CT scans for each subject studied.
  • FIGS. 1 and 2 demonstrate the sequence of events that occur within the composite sponge carrier loaded with rhBMP-2.
  • On the far left of the figures are three CT sections equally spaced throughout the fusion mass at 2 months post-operative, showing that resorption of the composite sponge is just about complete due to the lack of radiopacity of the ceramic granules.
  • the three middle CT sections show these same three CT sections at four months with increased bone deposition where the carrier once resided.
  • the composite sponge has maintained the space within the soft tissue site for a sufficient enough period of time for the desired volume of new bone deposition to occur.
  • the far right three CT scans show even further bone deposition, remodeling and maturation with the formation of outer cortices around the periphery of the fusion masses by six months.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Composite Materials (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Osteogenic sponge compositions having enhanced osteoinductive properties for use in bone repair are described. The compositions include a quickly resorbable porous carrier, a more slowly resorbed mineral scaffold and an osteogenic factor, preferably a bone morphogenetic protein. The compositions enable increased osteoinductive activity while retaining a reliable scaffold for the formation of new bone at an implant site. Methods for therapeutic use of the compositions are also described.

Description

HIGHLY-MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS,
AND USES THEREOF
REFERENCE TO RELATED APPLICATION
This application claims the benefit of U.S. Patent Application Serial No. 60/ 1 18,615 filed February 4, 1999, which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION The present invention relates generally to osteogenic compositions. Specifically, the present invention relates to an osteogenic sponge composition effective for the induction of new bone growth in animals.
BACKGROUND OF THE INVENTION
Bone grafting has been commonly used to augment healing in the treatment of a broad range of musculoskeletal disorders. This procedure has several disadvantages. If the bone material is obtained from donors of the same species, such as an allograft, an increased risk of disease transmission and immune reaction exists. Bone material surgically removed from the patient, known as an autograft, is also undesirable because a sufficient amount of autogenous bone may not be available and the additional surgery necessary to obtain the autograft increases the risk of infection. Due to the need for safer bone graft materials, efforts have been directed to finding bone graft substitutes. Candidate compositions include collagen and a bioceramic, such as hydroxyapatite, as these components are the chief structural materials in bone tissue. Bioceramics provide a porous matrix which encourages some new bone growth but, when used in powdered form, give rise to foreign body-giant cell reactions. Other compositions include demineralized bone powder and collagen. The osteogenic potential of these compositions have been found to be less than satisfactory.
The discovery of osteogenic factors and their application to bone graft substitute compositions has increased the effectiveness of the above-mentioned compositions. Although many preparations purport to be effective in bone repair in vertebrates, including higher animals such as primates, most of the experimentation done with the compositions have involved lower animals, such as mice and rats.
In light of this background, there remains a need for improved osteogenic compositions and methods that effectively induce bone growth in higher animals, including primates.
SUMMARY OF THE INVENTION
The invention provides in one preferred embodiment an osteogenic sponge composition useful for the induction of new bone growth in a mammal. This composition includes a resorbable sponge matrix material and an osteogenic factor, preferably one that preferably stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in the sponge matrix material. The resorbable sponge matrix material is desirably a three- dimensionally stable yet flexible material, facilitating its use as an implant. The osteogenic factor is usually incorporated in an amount that causes an increased rate of resorption of said sponge matrix material in a mammal. The composition also includes a particulate mineral having an average particle diameter of at least about 0.5 mm embedded in the resorbable sponge matrix material, wherein the particulate mineral present in a weight ratio of at least 4: 1 relative to the resorbable sponge matrix material so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor. More preferred compositions are even more highly mineralized, for example wherein the particulate mineral is present in a weight ratio of at least about 10: 1 relative to the resorbable sponge matrix material. The particulate mineral is desirably formed of a synthetic calcium phosphate ceramic or of bone, especially cortical bone. The osteogenic factor is most preferably BMP-2 or LMP, or comprises a nucleotide sequence encoding BMP-2 or LMP.
Another embodiment of the present invention provides a method for inducing bone growth in a primate. The method includes a first step of providing an osteogenic sponge composition having a resorbable sponge matrix material and an osteogenic factor that stimulates osteoblasts and osteoclasts incorporated in the sponge matrix material in an amount that causes an increased rate of resorption of the sponge matrix material in the primate. Particulate mineral having an average particle diameter of at least about 0.5 mm is embedded in said resorbable sponge matrix material and present in a weight ratio of at least 4: 1 relative to the resorbable sponge matrix material, so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor. This osteogenic sponge composition is implanted in the primate in a void in which bone growth is desired, with the osteogenic sponge composition providing a scaffold for a duration sufficient for osteoid ingrowth through the void. Particularly preferred methods involve bone ingrowth to attain spinal fusions in humans.
Another preferred embodiment of the invention provides an osteogenic sponge composition effective for the induction of new bone growth in a mammal (especially a primate) that includes a carrier consisting essentially of a resorbable sponge matrix with particulate mineral embedded in the resorbable sponge matrix, wherein the particulate mineral is present in an amount constituting at least about 95% by weight of the carrier. An osteogenic factor that stimulates osteoblasts and osteoclasts is incorporated in said carrier.
A still further aspect of the invention provides a highly mineralized sponge implant device consisting essentially of a resorbable sponge matrix formed of collagen and having particulate biocompatible mineral embedded within said matrix. In this embodiment, the device is comprised 1% to 3% by weight of the collagen and 97% to 99% by weight of the particulate biocompatible mineral. In another inventive feature, an osteogenic factor can be incorporated in such an implant.
A further embodiment of the invention provides an interbody spinal fusion device that includes a load bearing member sized for insertion between adjacent vertebrae and any one of the aforementioned compositions retained by the load bearing member. Such fusion devices can be used in inventive interbody spinal fusion methods mammals, wherein the devices are appropriately implanted to facilitate spinal fusion.
A particular feature of the present invention relates to the discovery that the inclusion of an osteogenic factor, especially an osteoblast- and osteoclast-stimulating osteogenic factor, in a resorbable sponge composition causes a substantially accelerated resorption of the sponge. This rapid resorption can diminish or eliminate the capacity of the sponge composition to effectively stimulate and support new bone formation in a void filled with the sponge composition. This is particularly the case in primates, including humans, in which the rate of new bone formation is relatively slow. Objects of the present invention are to provide osteogenic sponge compositions effective for the induction of bone growth in mammals, particularly primates, including humans, and related methods and devices. These and other objects and advantages of the present invention will become apparent upon reading the descriptions herein. BRIEF DESCRIPTION OF THE FIGURES
FIGs. 1 and 2 depict a digitized images of computerized tomography (CT) scans of an L4-L5 posterolateral spinal fusions performed on rhesus monkeys as described in Example 5 (top panels, section through superior transverse processes; middle panels, section through disc space; lower panels, section through inferior transverse processes).
DESCRIPTION OF THE PREFERRED EMBODIMENTS
For the purposes of promoting an understanding of the principles of the invention, reference will now be made to preferred embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications of the invention, and such further applications of the principles of the invention as illustrated herein, being contemplated as would normally occur to one skilled in the art to which the invention relates.
As described above, the invention relates in certain aspects to osteogenic sponge compositions effective for the induction of new bone growth in mammals and methods for inducing bone growth in mammals. The present invention features osteogenic sponge compositions effective for use in primates, wherein the compositions exhibit high osteoinductive potential and provide a lasting mineral scaffold to support bone ingrowth. Such preferred compositions include a porous, resorbable sponge carrier, such as collagen in sponge form, and an osteogenic factor that stimulates the action of both osteoblasts (which biologically facilitate the formation of bone) and osteoclasts (which biologically facilitate the resorption of bone). In accordance with the present invention, it has been found that the incorporation of an effective inductive amount of an osteogenic factor, such as a bone morphogenetic protein (BMP), stimulates osteoclasts to such a level that a porous resorbable carrier is quickly resorbed and, in the absence of a high mineral component in the composition, causes the performance of the composition to suffer in some cases to the extent that the observation of substantial bone ingrowth is sporadic. Although such non-mineralized sponge compositions may be highly effective for repair of bone defects in lower animals, such as mice, that have a faster bone growth rate, they are less effective in large animals such as primates, including humans.
Accordingly, a feature of the present invention is the provision of an osteogenic composition in the form of a sponge that includes a substantial amount of a relatively slowly-resorbed mineral component that remains at the implant site after the carrier has been rapidly resorbed, in order to provide a scaffold for new bone formation that is not prematurely resorbed due to the osteoclastic potentiation by the bone morphogenic protein in the composition. The present invention also provides methods for using such osteogenic compositions in treatment of bone trauma, disease and defects, for artificial arthrodeses and for other treatment where new bone formation is desired, especially in primates, including humans.
The sponge matrix material is preferably collagenous. A wide variety of collagen materials are suitable for the sponge matrix. Naturally occurring collagens may be subclassified into several different types depending on their amino acid sequence, carbohydrate content and presence or absence of disulfide crosslinks. Types I and III collagen are two of the most common subtypes of collagen. Type I collagen is present in skin, tendon and bone whereas Type III collagen is found primarily in skin. The collagen in the composition may be obtained from skin, bone, tendon, or cartilage and purified by methods known in the art. Alternatively, the collagen may be purchased commercially. The collagen in the composition is preferably Type I bovine collagen. The collagen carrier can further be atelopeptide collagen and/ or telopeptide collagen. Moreover, both non-fibrillar and fibrillar collagen may be used. Non-fibrillar collagen is collagen that has been solubilized and has not been reconstituted into its native fibrillar form.
The sponge carrier may also be formed of other natural or synthetic polymeric materials, in addition to or as an alternative to collagen. For example, the sponge carrier may be formed of gelatin (e.g. foamed gelatin), in addition collagen or as an alternative to collagen. Other natural and synthetic polymers are also known for the formation of biocompatible sponge materials, and can be used herein.
As indicated above, preferred compositions of the invention also include an osteoinductive factor, such as an osteoinductive protein or a nucleotide sequence encoding an osteoinductive protein operably associated with a promoter (e.g. provided in a vector such as a viral vector) which drives expression of the gene in the animal recipient to produce an effective amount of the protein. The osteogenic factor utilized in the present invention can be one that stimulates production or activity of osteoblasts and osteoclasts. The factor is preferably a bone morphogenetic protein (BMP) or a LIM mineralization protein (LMP), or comprises a nucleotide sequence encoding a BMP or LMP. Recombinant human BMPs are preferred, and may be commercially obtained or prepared as described and known in the art, e.g. in U.S. Patent Nos. 5, 187,076 to Wozney et al.; 5,366,875 to Wozney et al.; 4,877,864 to Wang et al.; 5, 108,932 to Wang et al.; 5, 1 16,738 to Wang et al.; 5,013,649 to Wang et al.; 5, 106,748 to Wozney et al; and PCT Patent Nos. WO93/00432 to Wozney et al.; WO94/2693 to Celeste et al.; and WO94/26892 to Celeste et al. Further, the osteoinductive factor may be isolated from bone. Methods for isolating BMP from bone are described in U.S. Patent no. 4,294,753 to Urist and Urist et al., PNAS 371, 1984. Recombinant human BMP-2 (rhBMP-2), recombinant human BMP-4 (rhBMP-4), recombinant human BMP- 7 (rhBMP-7) or heterodimers thereof are most preferred. The osteoinductive factor may also be LIM mineralization protein (LMP) or a suitable vector incorporating a gene encoding the same operably associated with a promotor, as described in WO99/06563 (see also genbank accession No. AF095585). When such vectors are employed as osteogenic factors in accordance with the invention, they are preferably delivered in conjunction with cells, for example autologous cells from the recipient of the implant. Most preferably the vector is delivered in conjunction with autologous white blood cells derived from bone marrow or peripheral blood of the recipient. These cells may be applied to the sponge composition along with the osteogenic factor prior to implantation.
The particulate mineral component includes a natural or synthetic mineral that is effective in providing a scaffold for bone ingrowth as the resorbable carrier is resorbed. The mineral may be, for example, bone, especially cortical bone, or a synthetic bioceramic such as a biocompatible calcium phosphate ceramic. Illustrative ceramics include tricalcium phosphate, hydroxyapatite, and biphasic calcium phosphate. These mineral components may be purchased commercially or obtained or synthesized by methods known in the art.
Biphasic calcium phosphate is a particularly preferred synthetic ceramic for use in the invention. Desirably, such biphasic calcium phosphate with have a tricalcium phosphate:hydroxyapatite weight ratio of about 50:50 to about 95:5, more preferably about 70:30 to about 95:5, even more preferably about 80:20 to about 90: 10, and most preferably about 85: 15.
In general, the amount of mineral in the osteogenic sponge composition must be sufficient to provide a scaffold that will remain in the patient for a period of time sufficient for the formation of osteoid in the void for which bone growth is desired. Typically, this period of time will be about 6 to about 8 weeks. The minimum level of mineral that must be present in the composition is also dependent on the activity of the BMP in the composition; the higher the activity of the BMP, the greater the content of the mineral matrix required to counter the osteoclastic potentiation of the BMP. The rate of resorption of the resorbable carrier also increases as the BMP concentration increases.
In preferred aspects of the invention, the particulate minera resorbable sponge matrix weight ratio will be at least about 4: 1, more preferably at least about 10: 1. In particularly preferred sponge implants, the particulate mineral will constitute at least 95% by weight of the sponge implant. For example, highly effective sponge carrier devices are provided wherein they comprise about 97% to about 99% by weight particulate mineral and about 1% to about 3% of the collagen or other sponge-forming matrix material. Moreover, it is preferred that the mineral component have an average particle size of at least about 0.5 mm, more preferably about 0.5 mm to about 5 mm, and most preferably about 1 mm to about 3 mm. To make the sponge implant, a collagen slurry may be formed as known and preferably is chilled to increase its viscosity to help suspend the porous particulate mineral component. The porous particulate mineral is dispersed into the collagen slurry and gently mixed. After the porous particulate mineral component is uniformly dispersed in the slurry, the slurry is poured into sterile trays or other forms and freeze dried. The sheets of composite sponge are then removed from the freeze drier and exposed to a gluteraldehyde cross-linking agent. The composite sponge formed is generally three -dimensionally stable and can be sterilized and packaged in accordance with known procedures.
The dimensions of the sponge produced may vary depending on the application. Dimensions of a typical sponge are, for example, about 10 cm (length) x 7.5 cm (width) x 0.35 cm (height).
As one example, BMP or other osteogenic factors may be included in the formed sponge by combining the BMP with a liquid carrier as known in the art and infusing the liquid into the sponge.
As further enhancements of the compositions of the present invention, those skilled in the art will readily appreciate that other osteogenic enhancing factors may be incorporated into the composition. Such additional factors include host compatible osteogenic progenitor cells, autographic bone marrow, allographic bone marrow, transforming growth factor-β, fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, microglobulin-β, antibiotics and steroids.
In yet another aspect of the invention, methods for inducing bone growth in mammals are provided. The methods include providing the above-described osteogenic sponge composition and implanting the composition at a site at which bone growth is desired, e.g., to treat a disease, defect or location of trauma, and/or to promote artificial arthrodesis. The hydrated sponge composition may be rolled up prior to packing the sponge into the implantation site.
Once in place, the osteogenic sponge composition will effectively induce and support ingrowth of bone into the desired area even in a primate such as a human that exhibits a relatively slow rate of bone formation compared to smaller mammals, such as rodents or rabbits. Although the collagen carrier is resorbed relatively quickly, the substantial mineral component remains as a scaffolding to support new bone growth in and through the desired area.
The above osteogenic sponge compositions of the present invention are especially advantageous when used in bones or bone portions that exhibit only low to moderate vascularization. Such low to moderate vascularized regions exhibit low rates of bone formation so rapid resorption of a carrier poses a problem. Examples of low to moderate vascularized sites include, for example, transverse processes or other posterior elements of the spine.
An especially preferred use of the sponge compositions of the present invention is as an implant to promote arthrodesis between vertebrae in spinal fusions in humans or other primates, including interbody, posterior and/or posterolateral fusion techniques. Although the rate of bone formation in the primate spine is relatively slow overall and thus will benefit generally from the present invention, the elements to be fused in posterior and posterolateral fusions exhibit particularly low levels of vascularization and thus fusions of these elements are expected to benefit markedly from the invention.
Moreover, the osteogenic sponge compositions can be incorporated with a load-bearing member used in a spinal fusion, including hollow spinal cages, dowels or other devices known in the art having a pocket, chamber or other mechanism for retaining the osteogenic sponge composition. The load-bearing member desirably will have a compressive strength of at least about 10,000 N. Suitable such load bearing members are described, for example in U.S. Patent Nos. 5522899, 5785710, 5776199 and 5814084, each of which is hereby incorporated by reference in its entirety.
Reference will now be made to specific examples using the processes described above. It is to be understood that the examples are illustrative and not limiting of the invention.
EXAMPLE 1 PREPARATION OF COLLAGEN SPONGE/
BONE PARTICLE COMPOSITE
12 grams of deproteinized cortical bone chips, 1-3 mm in size, were added to 12 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm x 10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETC) gas sterilization. EXAMPLE 2
PREPARATION OF COLLAGEN SPONGE/
SYNTHETIC CERAMIC COMPOSITE
12 grams of biphasic calcium phosphate particles, 1 mm in diameter, were added to 12 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm x 10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETC) gas sterilization.
EXAMPLE 3
PREPARATION OF COLLAGEN SPONGE/
BONE PARTICLE COMPOSITE
12 grams of deproteinized cortical bone chips, 1-3 mm in size, were added to 24 grams of collagen slurry (0.192 grams of collagen).
This composite slurry was poured into a 7.5 cm x 10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETC) gas sterilization.
EXAMPLE 4
PREPARATION OF COLLAGEN SPONGE/
SYNTHETIC CERAMIC COMPOSITE
12 grams of biphasic calcium phosphate particles, 1 mm in diameter, were added to 24 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm x 10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETC) gas sterilization. EXAMPLE 5
L4-L5 POSTEROLATERAL INTERTRANSVERSE PROCESS SPINAL FUSION STUDY
The present study was performed to determine the effect of the osteogenic sponge compositions of the present invention on spinal fusion.
The experimental group included two adult rhesus monkeys [Macaca mulatto). The monkeys were anesthetized with 3-5 mg/kg telazol intramuscularly (i.m.). The anesthesia was maintained with 1.5-2.0% isoflurane. After anesthesia was achieved, animals were shaved, prepared with betadine and sterily draped. The surgical site was infiltrated with 10-15 ml of 0.25% marcaine to aid with immediate postoperative analgesia. A midlineposterior skin incision was made over the lumbar spine. The paraspinal muscles were reflected using elevators, exposing the lamina and the transverse processes of the L4 and L5 vertebral bodies. The transverse processes of the two vertebrae to be fused were decorticated with an electric burr.
Composite sponges, having dimension of 3.5 cm x 1.4 cm x 0.35 cm, were prepared using techniques as described in Examples 1 and 2. The sponges included, on a weight basis, 97% biphasic calcium phosphate (15% hydroxyapatite and 85% tricalcium phosphate, 1 mm particle size) and 3% collagen. Recombinant human BMP-2 (rhBMP-2) was prepared at a concentration of 3.0 mg/ml in a buffered solution. Each sponge was infused with 1.5 ml of the rhBMP-2 solution.
The sponges were placed in the paraspinal bed directly on top of and bridging the two adjacent transverse processes. The sponges were placed bilaterally, with two sponges (one on top of the other) on each side of the spine, resulting in a total dose of 9 mg rhBMP-2 per implant site. The animals were allowed to recover and move around ad libitum without restrictions during the study period. The spines were manually assessed for fusion upon sacrifice
(2, 4 and 6 months) and determined to be fused based upon the absence of motion during attempted bending, and presence of histological bridging bone.
The fusions were also evaluated by CT scan at 2, 4 and 6 months after implantation. FIGS. 1 and 2 show the CT scans for each subject studied. FIGS. 1 and 2 demonstrate the sequence of events that occur within the composite sponge carrier loaded with rhBMP-2. On the far left of the figures are three CT sections equally spaced throughout the fusion mass at 2 months post-operative, showing that resorption of the composite sponge is just about complete due to the lack of radiopacity of the ceramic granules. The three middle CT sections show these same three CT sections at four months with increased bone deposition where the carrier once resided. The composite sponge has maintained the space within the soft tissue site for a sufficient enough period of time for the desired volume of new bone deposition to occur. Finally, the far right three CT scans show even further bone deposition, remodeling and maturation with the formation of outer cortices around the periphery of the fusion masses by six months.

Claims

What is claimed is:
1. An osteogenic sponge composition useful for the induction of new bone growth in a mammal, comprising: a resorbable sponge matrix material; an osteogenic factor, said osteogenic factor incorporated in said sponge matrix material in an amount that causes an increased rate of resorption of said sponge matrix material in a mammal; and particulate mineral having an average particle diameter of at least about 0.5 mm embedded in said resorbable sponge matrix material, said particulate mineral present in a weight ratio of at least 4: 1 relative to said resorbable sponge matrix material, so as to provide a scaffold for bone ingrowth in the presence of said osteogenic factor.
2. The osteogenic sponge composition of claim 1 , wherein said particulate mineral is present in a weight ratio of at least about 10: 1 relative to said resorbable sponge matrix material.
3. The osteogenic sponge composition of claim 1, wherein said osteogenic factor comprises a bone morphogenetic protein, a LIM mineralization protein, or a nucleotide sequence encoding a bone morphogenetic protein or a LIM mineralization protein.
4. The osteogenic sponge composition of claim 1, wherein said resorbable sponge matrix material includes collagen.
5. The osteogenic sponge composition of claim 3, wherein said resorbable sponge matrix material includes collagen.
6. The osteogenic sponge composition of claim 1 , wherein said particulate mineral is selected from the group consisting of bone particles and biocompatible synthetic calcium phosphate ceramics.
7. The osteogenic sponge composition of claim 6, wherein said particulate mineral comprises biphasic calcium phosphate.
8. The osteogenic sponge composition of claim 7, wherein said biphasic calcium phosphate has a porosity of at least about 50%.
9. The osteogenic sponge composition of claim 8, wherein said particulate mineral includes bone particles.
10. The osteogenic sponge composition of claim 9, wherein said bone particles are cortical bone particles.
11. The osteogenic sponge composition of claim 1 , which is comprised at least about 95% by weight of said particulate mineral.
12. The osteogenic sponge composition of claim 1, wherein said particulate mineral has an average particle size in the range of about 0.5 mm to about 5.0 mm.
13. The osteogenic sponge composition of claim 1, wherein said porous particulate mineral has an average particle size in the range of about 1 to about 2 mm.
14. The osteogenic sponge composition of claim 1 , wherein said osteogenic factor is a bone morphogenetic protein.
15. The osteogenic sponge composition of claim 14, wherein said bone morphogenetic protein is a recombinant human protein.
16. The osteogenic sponge composition of claim 15, wherein said bone morphogenetic protein is BMP-2 or BMP-7.
17. The osteogenic sponge composition of claim 16, further comprising an osteogenic enhancing factor selected from the group consisting of autographic bone marrow, allographic bone marrow, transforming growth factor-β, fibroblast growth factor, platelet- derived growth factor, insulin-like growth factor, microglobulin-β, and steroids.
18. An osteogenic sponge composition effective for the induction of new bone growth in a primate, comprising: a resorbable sponge matrix material; an osteogenic factor that stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in said sponge matrix material in an amount that causes an increased rate of resorption of said sponge matrix material in the primate; and particulate mineral having an average particle diameter of at least about 0.5 mm embedded in said resorbable sponge matrix material, said particulate mineral present in a weight ratio of at least 4: 1 relative to said resorbable sponge matrix material, so as to provide a mineral scaffold for a duration sufficient for osteoid ingrowth through an area in which said sponge composition is implanted.
19. The sponge composition of claim 18 wherein the primate is a human.
20. A method for inducing bone growth in a primate, comprising:
(a) providing an osteogenic sponge composition comprising: a resorbable sponge matrix material; an osteogenic factor that stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in said sponge matrix material in an amount that causes an increased rate of resorption of said sponge matrix material in the primate; and particulate mineral having an average particle diameter of at least about 0.5 mm embedded in said resorbable sponge matrix material, said particulate mineral present in a weight ratio of at least 4: 1 relative to said resorbable sponge matrix material, so as to provide a scaffold for bone ingrowth in the presence of said ostegenic factor; and
(b) implanting said osteogenic sponge composition in an area in which bone growth is desired in the primate, said osteogenic sponge composition providing a scaffold for a duration sufficient for osteoid ingrowth through an area in which said osteogenic sponge composition is implanted.
21. The method of claim 20, wherein said particulate mineral is present in a weight ratio of at least 10: 1 relative to said resorbable sponge matrix material.
22. The method of claim 21 , wherein said osteogenic factor comprises a bone morphogenetic protein, a LIM mineralization protein, or a nucleotide sequence encoding a bone morphogenetic protein or LIM mineralization protein.
23. The method of claim 20, wherein said resorbable sponge matrix material includes collagen.
24. The method of claim 22, wherein said resorbable sponge matrix material includes collagen.
25. The method of claim 20. wherein said particulate mineral is selected from the group consisting bone, a synthetic biocompatible calcium phosphate ceramic, or a mixture thereof.
26. The method of claim 25, wherein said porous particulate mineral comprises biphasic calcium phosphate.
27. The method of claim 26, wherein said biphasic calcium phosphate has a porosity of at least about 50%.
28. The method of claim 20, wherein said particulate mineral includes bone particles.
29. The method of claim 28, wherein said bone particles are cortical bone particles.
30. The method of claim 20, wherein said osteoinductive sponge composition is comprised at least about 95% by weight of said particulate mineral.
31. The method of claim 20, wherein said particulate mineral has an average particle size of about 0.5 mm to about 5.0 mm.
32. The method of claim 20, wherein said porous particulate mineral has an average particle size of about 1 to about 2 mm.
33. The method of claim 20, wherein said osteogenic factor is a bone morphogenetic protein.
34. The method of claim 33, wherein said bone morphogenetic protein is a recombinant human protein.
35. The method of claim 33, wherein said bone morphogenetic protein is BMP-2 or BMP-7.
36. The method of claim 20, wherein the primate is a human.
37. The method of claim 20, wherein the area is in the spine of said primate.
38. The method of claim 37, wherein the bone growth is induced to attain a spinal fusion.
39. The method of claim 38, wherein the spinal fusion is an interbody spinal fusion.
40. The method of claim 38, wherein the spinal fusion is a posterolateral spinal fusion.
41. The method of claim 38, wherein the spinal fusion includes a fusion between transverse processes of adjacent vertebrae.
42. An osteogenic sponge composition for the induction of new bone growth in a primate, comprising: a carrier consisting essentially of a resorbable sponge matrix with particulate mineral embedded in said resorbable sponge matrix, said particulate mineral present in an amount constituting at least about 95% by weight of said carrier; and an osteogenic factor.
43. A highly mineralized sponge implant device consisting essentially of a resorbable sponge matrix formed of collagen and having particulate biocompatible mineral embedded within said matrix, said device comprised 1% to 3% by weight of the collagen and 97% to 99% by weight of the particulate biocompatible mineral.
44. The device of claim 42 wherein the particulate biocompatible mineral comprises bone particles.
45. The device of claim 42 wherein the particulate biocompatible mineral includes a synthetic ceramic.
46. The device of claim 44 wherein the ceramic material includes a calcium phosphate ceramic.
47. The device of claim 45 wherein the calcium phosphate ceramic is biphasic calcium phosphate.
48. An osteogenic implant, comprising: a resorbable matrix carrier comprised 1% to 3% by weight of collagen in sponge form and 97% to 99% by weight of a particulate biocompatible mineral embedded within said collagen; and an osteogenic factor.
49. An interbody spinal fusion device, comprising: a load bearing member sized for insertion between adjacent vertebrae; and a composition according to any of claims 1-19 and 42-48 retained by said load bearing member.
50. A method for interbody spinal fusion in a mammal, comprising implanting between adjacent vertebrae in the mammal an interbody spinal fusion device according to claim 49.
EP00905989A 1999-02-04 2000-02-04 Highly-mineralized osteogenic sponge compositions, and uses thereof Expired - Lifetime EP1150726B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11861599P 1999-02-04 1999-02-04
US118615P 1999-02-04
PCT/US2000/003043 WO2000045871A1 (en) 1999-02-04 2000-02-04 Highly-mineralized osteogenic sponge compositions, and uses thereof

Publications (2)

Publication Number Publication Date
EP1150726A1 true EP1150726A1 (en) 2001-11-07
EP1150726B1 EP1150726B1 (en) 2003-11-05

Family

ID=22379695

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00905989A Expired - Lifetime EP1150726B1 (en) 1999-02-04 2000-02-04 Highly-mineralized osteogenic sponge compositions, and uses thereof

Country Status (9)

Country Link
US (3) US7563455B2 (en)
EP (1) EP1150726B1 (en)
JP (1) JP2002536077A (en)
AT (1) ATE253385T1 (en)
AU (1) AU772682B2 (en)
CA (1) CA2362049A1 (en)
DE (1) DE60006356T2 (en)
ES (1) ES2209820T3 (en)
WO (1) WO2000045871A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529764A1 (en) 2011-05-31 2012-12-05 Curasan AG Biodegradable composite material
US8497236B2 (en) 1998-02-13 2013-07-30 Zimmer Orthobiologics, Inc. Implantable putty material
US8613938B2 (en) 2010-11-15 2013-12-24 Zimmer Orthobiologics, Inc. Bone void fillers
US8690874B2 (en) 2000-12-22 2014-04-08 Zimmer Orthobiologics, Inc. Composition and process for bone growth and repair
US8742072B2 (en) 2006-12-21 2014-06-03 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2242600T3 (en) * 1999-02-04 2005-11-16 Sdgi Holdings, Inc. COMPOSITIONS OF OSTEOGENIC PASTE AND ITS USES.
ATE253385T1 (en) * 1999-02-04 2003-11-15 Sdgi Holdings Inc HIGHLY MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS AND THEIR USE
US7435260B2 (en) * 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
ES2319506T3 (en) * 2000-10-24 2009-05-08 Warsaw Orthopedic, Inc. METHODS AND DEVICES OF VERTEBRAL FUSION.
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
AU2002308204B9 (en) 2001-11-19 2008-06-12 Scil Technology Gmbh Device having osteoinductive and osteoconductive properties
JP2003169845A (en) * 2001-12-07 2003-06-17 Japan Science & Technology Corp Sponge-like porous apatite-collagen composite, sponge-like superporous apatite-collagen composite and method of manufacturing the same
TW200400062A (en) 2002-04-03 2004-01-01 Mathys Medizinaltechnik Ag Kneadable, pliable bone replacement material
US7166133B2 (en) * 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
DK1539261T3 (en) 2002-09-10 2006-08-07 Scil Technology Gmbh Metal implant coated under reduced oxygen concentration with osteoinductive protein
WO2004041319A1 (en) * 2002-11-07 2004-05-21 Pentax Corporation Therapeutic device for osteogenesis
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
US8734421B2 (en) 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
EP1671662A4 (en) * 2003-08-27 2010-12-15 Makoto Ogiso Structural body constituted of biocompatible material impregnated with fine bone dust and process for producing the same
US7666230B2 (en) 2003-12-08 2010-02-23 Depuy Products, Inc. Implant device for cartilage regeneration in load bearing articulation regions
US7189263B2 (en) * 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US20050192675A1 (en) * 2004-03-01 2005-09-01 Robinson Dane Q. Device for use in stimulating bone growth
US9220595B2 (en) 2004-06-23 2015-12-29 Orthovita, Inc. Shapeable bone graft substitute and instruments for delivery thereof
WO2006031196A1 (en) * 2004-09-14 2006-03-23 Agency For Science, Technology And Research Porous biomaterial-filler composite and a method for making the same
US7722895B1 (en) * 2004-09-20 2010-05-25 Warsaw Orthopedic, Inc. Osteogenic implants with combined implant materials, and materials and methods for same
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US20060083769A1 (en) * 2004-10-14 2006-04-20 Mukesh Kumar Method and apparatus for preparing bone
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7670384B2 (en) * 2004-10-14 2010-03-02 Biomet Manufacturing Corp. Bone graft composition comprising a bone material and a carrier comprising denatured demineralized bone
DE102005016443A1 (en) * 2004-11-23 2006-05-24 Ossacur Ag Bioabsorbable and mineralized material, useful for filling of bone defects, comprises a collagen matrix from aggregated collagen chains, where only the surface of the aggregated collagen chain is mineralized
US20090155332A1 (en) * 2005-02-25 2009-06-18 Eugene Sherry Replacement bone tissue
AU2006236548A1 (en) 2005-04-15 2006-10-26 Musculoskeletal Transplant Foundation Vertebral disc repair
US8506646B2 (en) * 2005-04-29 2013-08-13 Warsaw Orthopedic, Inc. Multi-purpose medical implant devices
US7857853B2 (en) * 2005-04-29 2010-12-28 Sdgi Holdings, Inc Synthetic loadbearing collagen-mineral composites useful for spinal implants, and methods of manufacture
US8092548B2 (en) * 2005-06-22 2012-01-10 Warsaw Orthopedic, Inc. Osteograft treatment to promote osteoinduction and osteograft incorporation
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US20070077267A1 (en) * 2005-10-03 2007-04-05 Sdgi Holdings, Inc. Bioactive composite implants
US9005646B2 (en) 2005-10-12 2015-04-14 Lifenet Health Compositions for repair of defects in tissues, and methods of making the same
US9132208B2 (en) * 2008-08-07 2015-09-15 Lifenet Health Composition for a tissue repair implant and methods of making the same
NZ571113A (en) 2005-11-17 2012-02-24 Biomimetic Therapeutics Inc Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix
US7824703B2 (en) 2006-02-01 2010-11-02 Warsaw Orthopedics, Inc. Medical implants with reservoir(s), and materials preparable from same
US7939092B2 (en) 2006-02-01 2011-05-10 Warsaw Orthopedic, Inc. Cohesive osteogenic putty and materials therefor
CA2641860C (en) 2006-02-09 2015-07-14 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
US7833270B2 (en) * 2006-05-05 2010-11-16 Warsaw Orthopedic, Inc Implant depots to deliver growth factors to treat osteoporotic bone
US9161967B2 (en) * 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
CA2656278C (en) 2006-06-30 2016-02-09 Biomimetic Therapeutics, Inc. Compositions and methods for treating rotator cuff injuries
EP2076220A2 (en) 2006-07-25 2009-07-08 Musculoskeletal Transplant Foundation Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
US8524265B2 (en) * 2006-08-17 2013-09-03 Warsaw Orthopedic, Inc. Medical implant sheets useful for tissue regeneration
WO2008073628A2 (en) 2006-11-03 2008-06-19 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures
US20080147197A1 (en) * 2006-12-14 2008-06-19 Mckay William F Biodegradable osteogenic porous biomedical implant with impermeable membrane
US8048857B2 (en) * 2006-12-19 2011-11-01 Warsaw Orthopedic, Inc. Flowable carrier compositions and methods of use
US20080195476A1 (en) * 2007-02-09 2008-08-14 Marchese Michael A Abandonment remarketing system
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
WO2008128342A1 (en) * 2007-04-18 2008-10-30 Mcgill University Composition for enhancing bone formation
EP2014256A1 (en) 2007-07-12 2009-01-14 Straumann Holding AG Composite bone repair material
EP2185637B1 (en) 2007-09-19 2013-04-03 SurModics, Inc. Biocompatible foams, systems, and methods
US20090110637A1 (en) * 2007-10-26 2009-04-30 Warsaw Orthopedic, Inc. LMP and Regulation of Tissue Growth
US9056150B2 (en) * 2007-12-04 2015-06-16 Warsaw Orthopedic, Inc. Compositions for treating bone defects
AU2009212151C1 (en) * 2008-02-07 2015-09-17 Biomimetic Therapeutics, Llc Compositions and methods for distraction osteogenesis
EP2265220A1 (en) 2008-03-05 2010-12-29 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US8840913B2 (en) * 2008-03-27 2014-09-23 Warsaw Orthopedic, Inc. Malleable multi-component implants and materials therefor
PL2288376T3 (en) 2008-04-18 2016-07-29 Collplant Ltd Methods of generating and using procollagen
US9492375B2 (en) * 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US8039433B2 (en) * 2008-08-19 2011-10-18 Warsaw Orthopedic, Inc. Osteogenic compositions containing a coloring agent
NZ602861A (en) * 2008-09-09 2014-03-28 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
WO2010102266A1 (en) * 2009-03-05 2010-09-10 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects
US20120089232A1 (en) 2009-03-27 2012-04-12 Jennifer Hagyoung Kang Choi Medical devices with galvanic particulates
US20110060419A1 (en) * 2009-03-27 2011-03-10 Jennifer Hagyoung Kang Choi Medical devices with galvanic particulates
WO2011063165A1 (en) * 2009-11-18 2011-05-26 Affinergy, Inc. Methods and compositions for capture of cells
US8475824B2 (en) 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US8758791B2 (en) 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
EP2538791B1 (en) 2010-02-22 2015-04-08 BioMimetic Therapeutics, LLC Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
EP2569342B1 (en) 2010-05-11 2022-01-26 Howmedica Osteonics Corp. Organophosphorous, multivalent metal compounds,&polymer adhesive interpenetrating network compositions&methods
CN103079585B (en) 2010-08-20 2015-09-30 惠氏有限责任公司 Through the BMP of design
US8551525B2 (en) 2010-12-23 2013-10-08 Biostructures, Llc Bone graft materials and methods
US9358122B2 (en) 2011-01-07 2016-06-07 K2M, Inc. Interbody spacer
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
KR101883144B1 (en) * 2011-02-25 2018-07-31 신세스 게엠바하 Osteogenic promoting implants and methods of inducing bone growth
WO2012158527A2 (en) 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
US8998925B2 (en) 2011-06-20 2015-04-07 Rdc Holdings, Llc Fixation system for orthopedic devices
WO2012177759A1 (en) 2011-06-20 2012-12-27 Rdc Holdings, Llc System and method for repairing joints
US8920511B2 (en) 2011-11-17 2014-12-30 Allosource Multi-piece machine graft systems and methods
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
US9642933B2 (en) 2012-01-30 2017-05-09 Board Of Regents, The University Of Texas System Compositions comprising bioadhesives and methods of making the same
WO2013123509A1 (en) * 2012-02-17 2013-08-22 Bacterin International, Inc. Adjustable bioactive agent dispersion within a polymeric coating
US8697107B2 (en) 2012-04-27 2014-04-15 Warsaw Orthopedic, Inc. Flowable implant with crosslinkable surface membrane
US10207027B2 (en) 2012-06-11 2019-02-19 Globus Medical, Inc. Bioactive bone graft substitutes
US9585764B2 (en) * 2012-07-26 2017-03-07 Warsaw Orthopedic, Inc. Bone implant device
EP2941482B1 (en) * 2013-01-04 2020-11-25 Board Of Regents, The University Of Texas System Compositions comprising citrate and applications thereof
EP2958523B1 (en) 2013-02-22 2020-04-22 AlloSource Cartilage mosaic compositions and methods
WO2014138612A1 (en) 2013-03-07 2014-09-12 Allosource Consistent calcium content bone allograft systems and methods
BR112015016264A2 (en) * 2013-03-14 2017-07-11 Genzyme Corp thermosensitive bone growth compositions
CA2895140C (en) 2013-03-15 2021-07-13 Allosource Perforated osteochondral allograft compositions
EP2970882B1 (en) 2013-03-15 2018-11-28 AlloSource Cell repopulated collagen matrix for soft tissue repair and regeneration
US9486483B2 (en) 2013-10-18 2016-11-08 Globus Medical, Inc. Bone grafts including osteogenic stem cells, and methods relating to the same
US9539286B2 (en) 2013-10-18 2017-01-10 Globus Medical, Inc. Bone grafts including osteogenic stem cells, and methods relating to the same
US9579421B2 (en) 2014-02-07 2017-02-28 Globus Medical Inc. Bone grafts and methods of making and using bone grafts
US9463264B2 (en) 2014-02-11 2016-10-11 Globus Medical, Inc. Bone grafts and methods of making and using bone grafts
WO2015175983A1 (en) 2014-05-16 2015-11-19 Allosource Composite bone constructs and methods
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
EP3240563B1 (en) 2014-12-29 2020-12-09 Bioventus LLC Systems and methods for improved delivery of osteoinductive molecules in bone repair
EP3297694A1 (en) 2015-05-21 2018-03-28 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US10016529B2 (en) 2015-06-10 2018-07-10 Globus Medical, Inc. Biomaterial compositions, implants, and methods of making the same
US11426489B2 (en) 2015-06-10 2022-08-30 Globus Medical, Inc. Biomaterial compositions, implants, and methods of making the same
WO2017100339A1 (en) * 2015-12-07 2017-06-15 Nuvasive, Inc. Immunomodulation with implantation of cellular allograft bone into a non-bony site
US20170319750A1 (en) * 2016-05-09 2017-11-09 Bioventus, Llc Composite matrices designed for enhanced bone repair
MX2019012248A (en) 2017-04-13 2020-02-07 Septodont Ou Septodont Sas Ou Specialites Septodont Connective tissues, such as bone, dentin or pulp, regenerative material comprising calcium silicate.
EP3388092A1 (en) 2017-04-13 2018-10-17 Septodont ou Septodont SAS ou Specialites Septodont Connective tissues, such as bone, dentin or pulp, regenerative material comprising calcium silicate
US11452796B2 (en) 2017-06-30 2022-09-27 Allosource Cellular bone grafts, and methods of manufacture and use
US11896736B2 (en) 2020-07-13 2024-02-13 Globus Medical, Inc Biomaterial implants and methods of making the same
US11883302B2 (en) 2021-11-22 2024-01-30 Warsaw Orthopedic, Inc. Spinal implant having a compressible insert

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2967060D1 (en) 1979-12-18 1984-07-19 Oscobal Ag Bone replacement material and process for producing a bone replacement material
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4795804A (en) * 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US5001169A (en) * 1984-10-24 1991-03-19 Collagen Corporation Inductive collagen-based bone repair preparations
US4888366A (en) * 1984-10-24 1989-12-19 Collagen Corporation Inductive collagen-based bone repair preparations
US5273964A (en) 1985-03-20 1993-12-28 Lemons J E Inorganic and organic composition for treatment of bone lesions
US4992226A (en) 1985-03-28 1991-02-12 Collagen Corporation Method of making molds with xenogeneic collagen/mineral preparations for bone repair
US5246457A (en) 1985-03-28 1993-09-21 Collagen Corporation Xenogeneic collagen/mineral preparations in bone repair
US4776890A (en) 1985-12-18 1988-10-11 Collagen Corporation Preparation of collagen hydroxyapatite matrix for bone repair
US4780450A (en) 1985-12-20 1988-10-25 The University Of Maryland At Baltimore Physically stable composition and method of use thereof for osseous repair
US4743229A (en) 1986-09-29 1988-05-10 Collagen Corporation Collagen/mineral mixing device and method
US4865602A (en) * 1986-11-06 1989-09-12 Collagen Corporation Gamma irradiation of collagen/mineral mixtures
US4861733A (en) * 1987-02-13 1989-08-29 Interpore International Calcium phosphate bone substitute materials
WO1989004646A1 (en) * 1987-11-13 1989-06-01 Jefferies Steven R Bone repair material and delayed drug delivery
US5573771A (en) * 1988-08-19 1996-11-12 Osteomedical Limited Medicinal bone mineral products
US5106626A (en) * 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5231169A (en) * 1990-10-17 1993-07-27 Norian Corporation Mineralized collagen
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5626861A (en) * 1994-04-01 1997-05-06 Massachusetts Institute Of Technology Polymeric-hydroxyapatite bone composite
US5817327A (en) * 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
CN1134810A (en) * 1995-02-17 1996-11-06 索发默达纳集团股份有限公司 Improved interbody spinal fusion implants
MXPA97009909A (en) * 1995-06-06 2004-08-23 Gensci Regeneration Lab Inc Modified osteogenic materials.
US5702449A (en) * 1995-06-07 1997-12-30 Danek Medical, Inc. Reinforced porous spinal implants
CA2172917A1 (en) 1995-06-07 1996-12-08 Hugh R. Mcmullin Moldable collagen compositions for hard tissue repair and augmentation
US5776193A (en) 1995-10-16 1998-07-07 Orquest, Inc. Bone grafting matrix
ES2225870T3 (en) * 1996-02-29 2005-03-16 Bioactive Bone Substitute Oy, Ab OSTEOGENIC DEVICE AND ITS PREPARATION PROCEDURE.
EP2311471A3 (en) * 1996-04-19 2013-05-15 Osiris Therapeutics, Inc. Regeneration and augmentation of bone using mesenchymal stem cells
US5741261A (en) * 1996-06-25 1998-04-21 Sdgi Holdings, Inc. Minimally invasive spinal surgical methods and instruments
ATE357264T1 (en) * 1996-10-24 2007-04-15 Sdgi Holdings Inc CERAMIC IMPLANTS AND COMPOSITIONS WITH OSTEOINDUCTIVE ACTIVE INGREDIENTS
US5972368A (en) * 1997-06-11 1999-10-26 Sdgi Holdings, Inc. Bone graft composites and spacers
ATE253385T1 (en) * 1999-02-04 2003-11-15 Sdgi Holdings Inc HIGHLY MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS AND THEIR USE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0045871A1 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497236B2 (en) 1998-02-13 2013-07-30 Zimmer Orthobiologics, Inc. Implantable putty material
US8690874B2 (en) 2000-12-22 2014-04-08 Zimmer Orthobiologics, Inc. Composition and process for bone growth and repair
US8742072B2 (en) 2006-12-21 2014-06-03 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US8613938B2 (en) 2010-11-15 2013-12-24 Zimmer Orthobiologics, Inc. Bone void fillers
EP2529764A1 (en) 2011-05-31 2012-12-05 Curasan AG Biodegradable composite material
WO2012163532A2 (en) 2011-05-31 2012-12-06 Curasan Ag Biodegradable composite material
US9907884B2 (en) 2011-05-31 2018-03-06 Curasan Ag Biodegradable composite material

Also Published As

Publication number Publication date
US8399010B2 (en) 2013-03-19
ATE253385T1 (en) 2003-11-15
WO2000045871A1 (en) 2000-08-10
US7563455B2 (en) 2009-07-21
US8147862B2 (en) 2012-04-03
EP1150726B1 (en) 2003-11-05
CA2362049A1 (en) 2000-08-10
DE60006356D1 (en) 2003-12-11
ES2209820T3 (en) 2004-07-01
DE60006356T2 (en) 2004-09-09
US20020082694A1 (en) 2002-06-27
US20090196904A1 (en) 2009-08-06
AU2756800A (en) 2000-08-25
JP2002536077A (en) 2002-10-29
AU772682B2 (en) 2004-05-06
US20120141557A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
US8399010B2 (en) Highly-mineralized osteogenic sponge compositions and uses thereof
AU770196B2 (en) Osteogenic paste compositions and uses thereof
US8690874B2 (en) Composition and process for bone growth and repair
AU2011329054B2 (en) Bone void fillers
Levine et al. Bone morphogenetic protein promotes vascularization and osteoinduction in preformed hydroxyapatite in the rabbit
EP0616814A1 (en) Compositions for controlled release of biologically active TGF - beta
Breitbart et al. Tricalcium phosphate and osteogenin: a bioactive onlay bone graft substitute
JP2004262758A (en) Porous beta-tricalcium phosphate granule and method for producing the same
US20190117734A1 (en) System and Method for Multiphasic Release of Growth Factors
CA2868992C (en) System and method for multiphasic release of growth factors
US11596712B2 (en) Autologous bone graft substitute composition
JPH10151188A (en) Implant for ossification
WO2010050935A1 (en) Devices containing demineralized bone matrix particles
US20090061002A1 (en) Calcium phospate based delivery of growth and differentiation factors to compromised bone
Lee A Pilot Study to Compare the Activity of Different Bone Morphogenetic Protein Bioimplants In Vivo
Mekhail et al. Alternatives to Autogenous Bone Graft in Revision Lumbar Spine Surgery

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010904

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20011203

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031105

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031105

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031105

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20031105

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031105

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031105

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031105

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031105

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 60006356

Country of ref document: DE

Date of ref document: 20031211

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040204

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040205

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040205

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040205

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040205

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040228

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
LTIE Lt: invalidation of european patent or patent extension

Effective date: 20031105

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2209820

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040901

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20040205

26N No opposition filed

Effective date: 20040806

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050420

Year of fee payment: 6

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20040205

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20061031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228